<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sanofi Sa — News on 6ix</title>
<link>https://6ix.com/company/sanofi-sa-1</link>
<description>Latest news and press releases for Sanofi Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 06 May 2026 16:41:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sanofi-sa-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d5371fbeedb30cb6f6f608.webp</url>
<title>Sanofi Sa</title>
<link>https://6ix.com/company/sanofi-sa-1</link>
</image>
<item>
<title>Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1</title>
<link>https://6ix.com/company/sanofi-sa-1/news/sanofi-supports-alphadetect-to-accelerate-detection-of-alpha-1-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/sanofi-supports-alphadetect-to-accelerate-detection-of-alpha-1-1</guid>
<pubDate>Wed, 06 May 2026 16:41:00 GMT</pubDate>
<description>AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation, today announced Sanofi as one of its inaugural industry sponsors. This support further strengthens efforts to accelerate routine detection of Alpha-1 Antitrypsin Deficiency (Alpha-1), consistent with clinical practice guidelines.</description>
</item>
<item>
<title>Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial</title>
<link>https://6ix.com/company/sanofi-sa-1/news/dupixentr-dupilumab-demonstrates-improved-esophageal-function-in-eosinophilic-esophagitis-eoe-phase-4-trial-2</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/dupixentr-dupilumab-demonstrates-improved-esophageal-function-in-eosinophilic-esophagitis-eoe-phase-4-trial-2</guid>
<pubDate>Tue, 05 May 2026 11:00:00 GMT</pubDate>
<description>Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural changes and inflammation in the esophagus in adult patients with EoE at week 24 compared to placebo, in results presented at DDW These results reinforce the roles of IL-4 and IL-13, two of the key and central drivers of type 2 inflammation, in EoE EoE is a chronic, progressive disease that causes scarring and narrowing of the esophagus, making it difficult to</description>
</item>
<item>
<title>Sanofi invests $294M to expand AI Center of Excellence in Toronto and accelerate innovation for patients</title>
<link>https://6ix.com/company/sanofi-sa-1/news/sanofi-invests-dollar294m-to-expand-ai-center-of-excellence-in-toronto-and-accelerate-innovation-for-patients-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/sanofi-invests-dollar294m-to-expand-ai-center-of-excellence-in-toronto-and-accelerate-innovation-for-patients-1</guid>
<pubDate>Mon, 04 May 2026 17:00:00 GMT</pubDate>
<description>Sanofi, an R&D-driven, AI-powered biopharma company and Canada's largest biopharma manufacturer, is expanding its global Artificial Intelligence (AI) Centre of Excellence in Toronto, deepening its investment in Ontario and growing AI talent to develop and manufacture life-changing medicines and vaccines faster than ever before.</description>
</item>
<item>
<title>Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi</title>
<link>https://6ix.com/company/sanofi-sa-1/news/press-release-annual-general-meeting-of-april-29-2026-belen-garijo-appointed-as-director-and-chief-executive-officer-of-sanofi</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/press-release-annual-general-meeting-of-april-29-2026-belen-garijo-appointed-as-director-and-chief-executive-officer-of-sanofi</guid>
<pubDate>Wed, 29 Apr 2026 16:00:00 GMT</pubDate>
<description>Annual General Meeting of April 29, 2026 Belén Garijo appointed as Director and Chief Executive Officer of Sanofi Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened on April 29, 2026, under the chairmanship of Frédéric Oudéa. All resolutions were approved with a high level of shareholder support, in particular the appointment of Belén Garijo as a board member. In line with the Board’s decision of February 11, Belén Garijo will assume her duties as Chief Executive Offi</description>
</item>
<item>
<title>Press Release: Sanofi successfully prices 2.3 billion of bond issue</title>
<link>https://6ix.com/company/sanofi-sa-1/news/press-release-sanofi-successfully-prices-23-billion-of-bond-issue-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/press-release-sanofi-successfully-prices-23-billion-of-bond-issue-1</guid>
<pubDate>Fri, 24 Apr 2026 18:30:00 GMT</pubDate>
<description>Sanofi successfully prices 2.3 billion of bond issue Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches: €1,000 million fixed-rate notes, due May 2029, bearing interest at an annual rate of 3.000% €650 million fixed-rate notes, due May 2033, bearing interest at an annual rate of 3.375% €650 million fixed-rate notes, due May 2037, bearing interest at an annual rate of 3.750% The notes are being issued under Sanofi's Eur</description>
</item>
<item>
<title>Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses</title>
<link>https://6ix.com/company/sanofi-sa-1/news/press-release-sanofis-cenrifki-tolebrutinib-recommended-for-eu-approval-by-the-chmp-to-treat-secondary-progressive-multiple-sclerosis-without-relapses</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/press-release-sanofis-cenrifki-tolebrutinib-recommended-for-eu-approval-by-the-chmp-to-treat-secondary-progressive-multiple-sclerosis-without-relapses</guid>
<pubDate>Fri, 24 Apr 2026 10:09:00 GMT</pubDate>
<description>Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Recommendation based on the HERCULES phase 3 study which demonstrated that brain-penetrant Cenrifki (tolebrutinib) significantly delayed the onset of disability progression in non-relapsing SPMS Paris, April 24, 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval</description>
</item>
<item>
<title>Press Release: Q1 2026: double-digit sales and business EPS growth</title>
<link>https://6ix.com/company/sanofi-sa-1/news/press-release-q1-2026-double-digit-sales-and-business-eps-growth-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/press-release-q1-2026-double-digit-sales-and-business-eps-growth-1</guid>
<pubDate>Thu, 23 Apr 2026 05:30:00 GMT</pubDate>
<description>Q1 2026: double-digit sales and business EPS growth Paris, April 23, 2026 Q1 sales growth of 13.6% at CER1 and business earnings per share (EPS)2 of €1.88 Pharma launches sales increased by 49.6%, reaching €1.2 billion, driven primarily by Ayvakit, ALTUVIIIO, and SarclisaDupixent sales increased by 30.8% to €4.2 billion, a strong start to 2026Vaccines sales increased by 2.1% to €1.3 billion, benefiting from Heplisav-BResearch and Development expenses reached €1.7 billion, up by 1.5%Selling and g</description>
</item>
<item>
<title>Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria</title>
<link>https://6ix.com/company/sanofi-sa-1/news/press-release-sanofi-and-regenerons-dupixent-approved-in-the-us-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/press-release-sanofi-and-regenerons-dupixent-approved-in-the-us-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria</guid>
<pubDate>Wed, 22 Apr 2026 21:30:00 GMT</pubDate>
<description>Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin disease that causes itch and hives that can be debilitating for young children, especially for those whose disease remains uncontrolledCSU marks the f</description>
</item>
<item>
<title>Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children</title>
<link>https://6ix.com/company/sanofi-sa-1/news/press-release-sanofis-tzield-approved-in-the-us-to-delay-the-onset-of-stage-3-type-1-diabetes-in-young-children-5</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/press-release-sanofis-tzield-approved-in-the-us-to-delay-the-onset-of-stage-3-type-1-diabetes-in-young-children-5</guid>
<pubDate>Wed, 22 Apr 2026 05:05:00 GMT</pubDate>
<description>Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3Tzield is the first disease-modifying therapy for children aged one year and above diagnosed with stage 2 T1D Paris, April 22, 2026. The US Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from e</description>
</item>
<item>
<title>Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US</title>
<link>https://6ix.com/company/sanofi-sa-1/news/press-release-sanofi-provides-update-on-the-regulatory-submission-for-sarclisa-subcutaneous-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/press-release-sanofi-provides-update-on-the-regulatory-submission-for-sarclisa-subcutaneous-in-the-us</guid>
<pubDate>Wed, 22 Apr 2026 05:00:00 GMT</pubDate>
<description>Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target action date for its review of the biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) in combination with approved standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all currently approved US indications of Sarclisa intravenous (IV) fo</description>
</item>
<item>
<title>Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study</title>
<link>https://6ix.com/company/sanofi-sa-1/news/press-release-escmid-sanofis-nuvaxovid-covid-19-vaccine-showed-better-tolerability-than-mnexspike-in-head-to-head-study-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/press-release-escmid-sanofis-nuvaxovid-covid-19-vaccine-showed-better-tolerability-than-mnexspike-in-head-to-head-study-1</guid>
<pubDate>Sat, 18 Apr 2026 10:00:00 GMT</pubDate>
<description>ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tolerability profiles of these vaccines in adults in a real-world settingResults were presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Munich, Germany. Paris, April 18, 2026. Sanofi's protein-based non-mRNA COVID-19 vaccine Nuvaxovid (NVX-CoV</description>
</item>
<item>
<title>Sanofi: Information concerning the total number of voting rights and shares - March 2026</title>
<link>https://6ix.com/company/sanofi-sa-1/news/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-march-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-march-2026-1</guid>
<pubDate>Tue, 14 Apr 2026 16:30:00 GMT</pubDate>
<description>Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,424,365,088Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis</description>
</item>
<item>
<title>Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians</title>
<link>https://6ix.com/company/sanofi-sa-1/news/sanofi-becomes-market-authorization-holder-for-nuvaxovidr-in-canada-expanding-covid-19-vaccine-choices-for-canadians-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/sanofi-becomes-market-authorization-holder-for-nuvaxovidr-in-canada-expanding-covid-19-vaccine-choices-for-canadians-1</guid>
<pubDate>Thu, 09 Apr 2026 14:00:00 GMT</pubDate>
<description>Sanofi today announces it has become the market authorization holder in Canada for Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine. Nuvaxovid represents another step in Sanofi's commitment to building a diverse portfolio of best-in-class vaccines and addressing respiratory diseases for Canadians across their lifespan. Sanofi will make Nuvaxovid available in Canada for the fall 2026-2027 season.</description>
</item>
<item>
<title>Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents</title>
<link>https://6ix.com/company/sanofi-sa-1/news/sanofi-combined-general-meeting-of-april-29-2026-availability-of-preparatory-documents-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/sanofi-combined-general-meeting-of-april-29-2026-availability-of-preparatory-documents-1</guid>
<pubDate>Wed, 08 Apr 2026 16:00:00 GMT</pubDate>
<description>COMBINED GENERAL MEETING OF APRIL 29, 2026 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday April 29, 2026 at 2:30 p.m. (CET) at the Palais des Congrès – Amphithéâtre Bleu – 2, place de la Porte Maillot – 75017 Paris. The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the w</description>
</item>
<item>
<title>Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP</title>
<link>https://6ix.com/company/sanofi-sa-1/news/press-release-sanofis-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-in-asthma-and-crswnp-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/press-release-sanofis-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-in-asthma-and-crswnp-1</guid>
<pubDate>Tue, 07 Apr 2026 05:00:00 GMT</pubDate>
<description>Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig’s potential as a respiratory treatmentThe exploratory VELVET phase 2b study did not meet its primary endpoint in mo</description>
</item>
<item>
<title>Press release: Availability of the Q1 2026 aide-mémoire</title>
<link>https://6ix.com/company/sanofi-sa-1/news/press-release-availability-of-the-q1-2026-aide-memoire-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/press-release-availability-of-the-q1-2026-aide-memoire-1</guid>
<pubDate>Tue, 24 Mar 2026 06:30:00 GMT</pubDate>
<description>Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First quarter 2026 results (sanofi.com) Prepared each quarter, this document is intented to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi's Q1 2026 results will be published on April 23, 2026. About Sanofi Sanofi is an R</description>
</item>
<item>
<title>Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid</title>
<link>https://6ix.com/company/sanofi-sa-1/news/press-release-sanofi-and-regenerons-dupixent-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid-2</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/press-release-sanofi-and-regenerons-dupixent-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid-2</guid>
<pubDate>Tue, 24 Mar 2026 06:00:00 GMT</pubDate>
<description>Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placeboBP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesionsBP is the seventh approved ind</description>
</item>
<item>
<title>Kali Therapeutics Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Tri-Specific T-Cell Engager for Autoimmune Diseases</title>
<link>https://6ix.com/company/sanofi-sa-1/news/kali-therapeutics-announces-worldwide-exclusive-license-agreement-with-sanofi-for-next-generation-tri-specific-t-cell-engager-for-autoimmune-diseases-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/kali-therapeutics-announces-worldwide-exclusive-license-agreement-with-sanofi-for-next-generation-tri-specific-t-cell-engager-for-autoimmune-diseases-1</guid>
<pubDate>Mon, 23 Mar 2026 11:01:00 GMT</pubDate>
<description>Kali Therapeutics, a biotechnology company focused on the discovery and development of next-generation biologics, today announced that they have entered into a license agreement with Sanofi for a tri-specific T-cell engager, which has the potential to treat a broad range of B cell-mediated autoimmune diseases.</description>
</item>
<item>
<title>Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development</title>
<link>https://6ix.com/company/sanofi-sa-1/news/earendil-labs-announces-dollar787-million-in-financing-to-scale-ai-driven-biologics-discovery-and-development-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/earendil-labs-announces-dollar787-million-in-financing-to-scale-ai-driven-biologics-discovery-and-development-1</guid>
<pubDate>Fri, 20 Mar 2026 11:30:00 GMT</pubDate>
<description>Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised $787 million in financing rounds. The investment included participation by a group of leading global investors, including Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi, and Biotech Development Fund (created by Hillhouse and Pfizer), alongside other existing and new technology and healthcare-focused investors.</description>
</item>
<item>
<title>Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results</title>
<link>https://6ix.com/company/sanofi-sa-1/news/inhibrx-reports-fourth-quarter-and-fiscal-year-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/sanofi-sa-1/news/inhibrx-reports-fourth-quarter-and-fiscal-year-2025-financial-results-1</guid>
<pubDate>Thu, 19 Mar 2026 20:00:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. (the "Acquirer") and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials.</description>
</item>
</channel>
</rss>